The S&P 500's 3 Best-Performing Stocks So Far in 2026 Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026
Importantly, we covered multiple viewpoints: physicians whose clinics now use ePA, pharmacists who no longer juggle as many phone calls, and payers pledging to simplify processes under new accords ( [13] ) ( [63] )
Seek immediate medical help if you experience difficulty breathing or swallowing, severe rash or hives over large areas of your body, swelling of your face, lips, tongue, or throat, rapid heartbeat, or dizziness and fainting
Step 2: Start the process and submit your intake forms
[20] Consuming too much protein can also cause problems for GLP-1 users
Ingredient System Designed for Market Credibility